论文部分内容阅读
目的:探讨联合应用厄贝沙坦和丹参川芎嗪治疗糖尿病肾病的效果。方法 :对2013年1月~2015年1月我院收治的60例糖尿病肾病患者的临床资料进行回顾性分析,将其分为观察组与对照组,每组各30例患者。为观察组患者联合应用厄贝沙坦和丹参川芎嗪进行治疗,为对照组患者应用厄贝沙坦进行治疗,并在为其治疗3个月后对比分析其临床疗效。结果 :与进行治疗前相比,两组患者在进行治疗后其24h尿蛋白的指标显著降低,差异显著,有统计学意义(P<0.05)。与对照组患者相比,观察组患者在进行治疗后其Ccr的指标较高,Cr、24h蛋白尿的指标较低,差异显著,有统计学意义(P<0.05)。与对照组患者相比,观察组患者治疗的总有效率较高,差异显著,有统计学意义(P<0.05)。结论 :联合应用厄贝沙坦和丹参川芎嗪治疗糖尿病肾病的效果确切,可有效降低患者体内尿蛋白、血肌酐的水平,提高其体内肌酐的清除率,此法值得在临床上推广应用。
Objective: To investigate the effect of irbesartan and ligustrazine tetramethylpyrazine in the treatment of diabetic nephropathy. Methods: The clinical data of 60 patients with diabetic nephropathy admitted from January 2013 to January 2015 in our hospital were retrospectively analyzed. They were divided into observation group and control group, with 30 patients in each group. The patients in the observation group were treated with irbesartan and ligustrazine, and the patients in the control group were treated with irbesartan. The clinical efficacy of irbesartan was compared after 3 months of treatment. Results: Compared with those before treatment, the indexes of urinary protein in 24 hours and 24 hours after treatment were significantly decreased in both groups, with significant difference (P <0.05). Compared with the control group, the patients in the observation group had higher Ccr index and lower proteinuria index in Cr and 24h groups after treatment, with significant difference (P <0.05). Compared with the control group, the total effective rate of the treatment group in the observation group was significantly higher, with significant difference (P <0.05). Conclusion: The combined application of irbesartan and Ligustrazine tetramethylpyrazine treatment of diabetic nephropathy effect is exact, can effectively reduce the patient’s urinary protein, serum creatinine levels and improve their body creatinine clearance rate, this method worthy of clinical application.